Agent handling

United States Contrast Media Market Size, Share & Trends Analysis Report 2023: Chronic Diseases and Comorbidities Increase Demand for Imaging Tests - Forecast to 2030

Retrieved on: 
Lunedì, Gennaio 22, 2024
Diabetes, Conditional sentence, Death, MRI, Hospital, Cancer, Agent handling, CT scan, COVID-19, USD, FDA, Chronic condition, Health, Vaccine, Diagnosis, Magnetic resonance imaging, Prevalence, Medical imaging

Contrast Media Market Size, Share & Trends Analysis Report by Modality (Modality, Ultrasound, Magnetic Resonance Imaging (MRI), X-ray/Computed Tomography (CT Scan)), Type, Application, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Contrast Media Market Size, Share & Trends Analysis Report by Modality (Modality, Ultrasound, Magnetic Resonance Imaging (MRI), X-ray/Computed Tomography (CT Scan)), Type, Application, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. contrast media market size is expected to reach USD 3.36 billion by 2030, registering a CAGR of 4.1% from 2023 to 2030
    The increasing burden of chronic diseases is creating a demand for diagnostic imaging procedures, which, in turn, is driving the market growth.
  • Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market.
  • Hence, the increasing prevalence of complex comorbidities and long-term diseases is one of the major drivers of imaging tests and contrast agents; thus, contributing to the market growth.

PPG to review strategic alternatives for silica products business

Retrieved on: 
Martedì, Gennaio 9, 2024
Other Manufacturing, Construction & Property, Other Retail, Chemicals, Plastics, Specialty, Interior Design, Home Goods, Manufacturing, Other Construction & Property, Retail, Agent handling, Food, Environment, Disclosure, Creativity, Table tennis rubber, Growth

PPG (NYSE: PPG), a global leader in paints, coatings, and specialty materials, today announced that it has engaged Morgan Stanley & Co. LLC as financial advisor to assist in a review of strategic alternatives for its silica products business.

Key Points: 
  • PPG (NYSE: PPG), a global leader in paints, coatings, and specialty materials, today announced that it has engaged Morgan Stanley & Co. LLC as financial advisor to assist in a review of strategic alternatives for its silica products business.
  • PPG’s silica products business, which operates within the company’s specialty coatings and materials strategic business unit, manufactures and supplies precipitated silica products to major manufacturers around the world as performance-enhancing additives.
  • PPG Chairman and Chief Executive Officer, Tim Knavish, said, “We are exploring strategic alternatives for our silica products business to maximize its value for our shareholders and to ensure its continued success.
  • The silica products business is led by about 350 employees and manufactures products through dedicated facilities in Lake Charles, Louisiana and Delfzijl, The Netherlands.

Delysium introduces Lucy — the Operating System (OS) of the “YKILY” AI Agent Network

Retrieved on: 
Lunedì, Gennaio 1, 2024
Cloud, Ethereum, ZK, Google Cloud, Microsoft, Agent handling, Workflow, Agent, Unified, News, Architecture, AI, Internet, ID, Web 2.0, DEX, Hearing, BSC, Communication, Cryptocurrency

Today, with support from partners at Google Cloud and Microsoft, Delysium introduces a new version of Lucy, a significant step towards the development of the “YKILY” AI Agent Network.

Key Points: 
  • Today, with support from partners at Google Cloud and Microsoft, Delysium introduces a new version of Lucy, a significant step towards the development of the “YKILY” AI Agent Network.
  • Access to all agents is facilitated through Delysium’s Agent ID™ , a unique identifier and digital ID for AI Agents.
  • Alongside the Agent ID, Lucy will act as the operating system in a network of Autonomous Agents, enabling connections and access to various agents that provide services within the network.
  • Serving as the central hub for accessing a diverse range of AI Agents within the Delysium “YKILY” AI Agent Network, Lucy provides services such as intelligent trading, DEX aggregation, and targeted information.

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Retrieved on: 
Giovedì, Novembre 16, 2023
Pericarditis, Cardiology, Cannabidiol, University, American Heart Association, Research, CRDL, Working Group, Health, Therapy, Cardiac muscle, MMT, Pericardium, Agent handling, Knowledge, Poster, Fibrosis, TSX, Diagnosis, Facial muscles, Heart failure, Wound healing, Pharmaceutical industry

An abstract summarizing these results was submitted by the Company's international research collaborators from the University of Virginia and Houston Methodist DeBakey Heart & Vascular Center to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases ("MPD2023") held on November 15 and 16, 2023 in Belgrade, Serbia.

Key Points: 
  • An abstract summarizing these results was submitted by the Company's international research collaborators from the University of Virginia and Houston Methodist DeBakey Heart & Vascular Center to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases ("MPD2023") held on November 15 and 16, 2023 in Belgrade, Serbia.
  • The poster entitled "Cannabidiol Inhibits the Mesothelial to Mesenchymal Transition in Experimental Pericarditis" was presented for general viewing within the poster sessions of the MPD2023 Scientific Programme.
  • The 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases brings together a collaborative group dedicated to advancing knowledge, research, and clinical practises related to myocardial and pericardial diseases.
  • The Working Group aims to develop and disseminate guidelines, recommendations, and advancements in the field, ultimately enhancing patient care and outcomes for individuals affected by myocardial and pericardial diseases within the European and global medical community.

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

Retrieved on: 
Mercoledì, Dicembre 13, 2023
PDUFA date, Constipation, Risk, Tendon rupture, Moyamoya disease, FDA, Fatigue, Health, Bempedoic acid, Fetus, Back pain, Agent handling, Sinusitis, Pain, PDUFA, Diet, Uric acid, CLEAR, ATP, Safety, Kidney, Bronchitis, Food, Pregnancy, Mortality, Angioedema, Therapy, CVD, ANN, Esperies, Tablet, Patient, Ezetimibe, Spasm, Anaphylaxis, Upper respiratory tract infection, Diarrhea, Anemia, Disease, ESPR, Rupture, Incidence, Abdominal pain, Urinary tract infection, Gout, Hypersensitivity, Use, Esperion Therapeutics, Arthralgia, Rash, Pharmaceutical industry

ANN ARBOR, Mich., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has approved an updated LDL-cholesterol lowering indication for NEXLETOL and NEXLIZET to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations. Additionally, the maximally tolerated qualifier for statin use has been removed, and the prior limitation of use stating “the effect of NEXLIZET or NEXLETOL on cardiovascular morbidity and mortality has not been determined” has also been removed.

Key Points: 
  • These applications were accepted by the FDA which issued a PDUFA, or action, date of March 31, 2024.
  • The Company’s EMA applications also remain on track, with anticipated approval in the first half of 2024.
  • Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels which may lead to gout.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Global Wheat & Rice Flour Substitute-Resistant Starch Market Analysis Report 2023-2030: Opportunities in Growing Demand For Non-GMO and Clean Label Food Ingredients - ResearchAndMarkets.com

Retrieved on: 
Martedì, Dicembre 5, 2023
Retail, Agriculture, Natural Resources, Food, Beverage, Starch, Nutritional science, ADM, Tate & Lyle, Cargill, Pea, Food court, The Non-GMO Project, Application, Snack, Fruit, USD, Condiment, Vegetable, Food industry, Bread, Roquette, Agent handling, Growth, Bakery, Wheat, Roquette Frères, Flour, Ingredion

Bakery products are projected to hold a significant market share in the global wheat & rice flour-resistant starch market in 2022 in terms of value.

Key Points: 
  • Bakery products are projected to hold a significant market share in the global wheat & rice flour-resistant starch market in 2022 in terms of value.
  • Wheat & rice flour Substitute-Resistant starches are one of the major ingredients in the processing of bread and bakery products.
  • Furthermore, the market demand in North America is primarily driven by increased consumer preference for clean-label ingredients such as pea starch.
  • The key players operating in the wheat & rice flour Substitute-Resistant starch market include Tate & Lyle; Ingredion; MSP Starch Products; ADM; Roquette Freres; PURIS; and Cargill, Incorporated.

Hydrocolloidal Market to Reach $18.7 Billion, Globally, by 2032 at 5.6% CAGR: Allied Market Research

Retrieved on: 
Venerdì, Dicembre 8, 2023
Chart, Research, Consumer, Drink, Colloid, Phlorotannin, Urbanization, Lectin, Food, PDF, Polysaccharide, Biotechnology, Yogurt, Kainic acid, Ice cream, Cosmetics, Supply, Food industry, Table, Administration, Seaweed, Agent handling, Carrageenan, Transport, Restaurant, Pharmaceutical industry, Health, Sesquiterpene

PORTLAND, Ore., Dec. 8, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Hydrocolloidal Market by Product Type (Seaweed and Others), Function (Thickening Agent, Gelling Agent, Stabilizing Agent, and Others), End-use Industry (Food & Beverage, Pharmaceutical, Cosmetics, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global hydrocolloidal industry generated $10.9 billion in 2022, and is anticipated to generate $18.7 billion by 2032, witnessing a CAGR of 5.6% from 2023 to 2032.

Key Points: 
  • Restrictions on transportation and lockdown measures in various regions affected the production and distribution of raw materials and finished products.
  • ·  Impact on End-Use Industries: The hydrocolloidal market serves various industries, including food and beverages, pharmaceuticals, and cosmetics.
  • For example, the closure of restaurants and disruptions in food service had implications for certain food applications of hydrocolloids.
  • This has led to changes in dietary habits, increased demand for processed foods, and subsequently, a growing market for hydrocolloids.

Bracco Announces Long-Term Strategic Partnership with ulrich medical for Syringeless Magnetic Resonance Injectors

Retrieved on: 
Mercoledì, Novembre 22, 2023
Magnetic resonance imaging, Food, European Medicines Agency, Google Images, Patient, European, FDA, Agent handling, Partnership, Health, Gesellschaft mit beschränkter Haftung, Medical device, Medical imaging

MILAN, Italy, Nov. 22, 2023 /PRNewswire/ -- Bracco, a global leader in diagnostic imaging, and ulrich GmbH & Co. KG, a renowned German medical device manufacturer specializing in contrast media injectors and spinal implants, announced today a new long-term partnership that will bring a Bracco-branded, state-of-the-art MR injector to the United States under an exclusive private label arrangement. The two companies also announce the submittal of a 510(k) premarket notification to the FDA for the new device manufactured by ulrich GmbH & Co. KG.

Key Points: 
  • The two companies also announce the submittal of a 510(k) premarket notification to the FDA for the new device manufactured by ulrich GmbH & Co. KG.
  • Organ and tissue differentiation is frequently only possible with the use of contrast media in medical imaging.
  • For over 30 years, ulrich medical has offered contrast media injectors for use in computed tomography and magnetic resonance imaging.
  • "This strategic collaboration with Bracco Imaging to introduce this contrast media injector to the U.S. market represents our commitment to innovation and excellence in healthcare," said Klaus Kiesel, Chief Executive Officer of ulrich medical.

Bracco Announces Long-Term Strategic Partnership with ulrich medical for Syringeless Magnetic Resonance Injectors

Retrieved on: 
Mercoledì, Novembre 22, 2023
Magnetic resonance imaging, Food, European Medicines Agency, Google Images, Patient, European, FDA, Agent handling, Partnership, Health, Gesellschaft mit beschränkter Haftung, Medical device, Medical imaging

MILAN, Italy, Nov. 22, 2023 /PRNewswire/ -- Bracco, a global leader in diagnostic imaging, and ulrich GmbH & Co. KG, a renowned German medical device manufacturer specializing in contrast media injectors and spinal implants, announced today a new long-term partnership that will bring a Bracco-branded, state-of-the-art MR injector to the United States under an exclusive private label arrangement. The two companies also announce the submittal of a 510(k) premarket notification to the FDA for the new device manufactured by ulrich GmbH & Co. KG.

Key Points: 
  • The two companies also announce the submittal of a 510(k) premarket notification to the FDA for the new device manufactured by ulrich GmbH & Co. KG.
  • Organ and tissue differentiation is frequently only possible with the use of contrast media in medical imaging.
  • For over 30 years, ulrich medical has offered contrast media injectors for use in computed tomography and magnetic resonance imaging.
  • "This strategic collaboration with Bracco Imaging to introduce this contrast media injector to the U.S. market represents our commitment to innovation and excellence in healthcare," said Klaus Kiesel, Chief Executive Officer of ulrich medical.

Patriot Makes New Discovery at the Corvette Property as it Intercepts 100 m of Spodumene-Bearing Pegmatite at CV9, Quebec, Canada

Retrieved on: 
Giovedì, Novembre 23, 2023
FSE, Observation, The Company, CV13, ASX, CV5, Patriot, Proxy, NQ, Agent handling, Orientation, Lithium, Road, Rare-earth element, Printed circuit board, Exploration, CV9

Preliminary geological modelling indicates the CV9 Pegmatite significantly thickens to at least 80 m width at one location and remains open in multiple directions.

Key Points: 
  • Preliminary geological modelling indicates the CV9 Pegmatite significantly thickens to at least 80 m width at one location and remains open in multiple directions.
  • The magnitude of this variably mineralized pegmatite blow-out is significant, sharing similarities to those present at the CV5 Pegmatite in terms of depth and scale.
  • Eighteen (18) core holes (~4,000 m) have been completed in the inaugural drill program at the CV9 Pegmatite – sample assays are pending.
  • Darren L. Smith, Company Vice President of Exploration, comments: "This is a very strong start to the drill exploration at the CV9 Pegmatite.